MABVAX THERAPEUTICS INC has a total of 15 patent applications. Its first patent ever was published in 2014. It filed its patents most often in United States, Canada and Republic of Korea. Its main competitors in its focus markets pharmaceuticals, measurement and biotechnology are FREDAX AB, LYKERA BIOMED SA and ABBVIE STEMCENTRX LLC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 3 | |
#2 | Canada | 2 | |
#3 | Republic of Korea | 2 | |
#4 | WIPO (World Intellectual Property Organization) | 2 | |
#5 | Brazil | 1 | |
#6 | China | 1 | |
#7 | EPO (European Patent Office) | 1 | |
#8 | Hong Kong | 1 | |
#9 | Japan | 1 | |
#10 | South Africa | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Measurement | |
#3 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Analysing materials | |
#2 | Therapeutic chemical compounds | |
#3 | Peptides | |
#4 | Medical preparations |
# | Name | Total Patents |
---|---|---|
#1 | Scholz Wolfgang | 13 |
#2 | Sawada Ritsuko | 12 |
#3 | Sun Shu-Man | 7 |
#4 | Ritsuko Sawada | 2 |
#5 | Wolfgang Scholz | 2 |
#6 | Shu-Man Sun | 2 |
#7 | Sun Shu Man | 1 |
#8 | Sun Shuman | 1 |
#9 | Saw Ada Ritsuko | 1 |
Publication | Filing date | Title |
---|---|---|
KR20170041172A | Human monoclonal antibodies to ganglioside | |
WO2015053871A2 | NUCLEIC ACIDS ENCODING HUMAN ANTIBODIES TO SIALYL-LEWISa |